Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LRX712 · 2 trials · 2 indications
Magnetic resonance images (MRI) were obtained from the target knee to visualize and quantify changes in the volume of cartilage in the index region. The index region was defined as the combination of the femoral medial anterior (FMA), central (FMC) and posterior (FMP) cartilage subregions in the knee. Change from baseline in cartilage volume was analyzed using the mixed effects model for repeated measures (MMRM). The model included baseline, treatment, timepoint and treatment-timepoints as fixed effects, and participant as random effect. Missing data was assumed to be Missing at Random (MAR).
To evaluate Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) of LRX712 after a single i.a. injection in osteoarthritic patients
| Arm | Type | Description |
|---|---|---|
| LRX712 15 mg | EXPERIMENTAL | LRX712 15 mg was administered intra-articularly (i.a.) every four weeks, for a total of three administrations. |
| LRX712 25 mg | EXPERIMENTAL | LRX712 25 mg was administered i.a. every four weeks, for a total of three administrations. |
| LRX712 75 mg | EXPERIMENTAL | LRX712 75 mg was administered i.a. every four weeks, for a total of three administrations. |
| Placebo | PLACEBO_COMPARATOR | Placebo was administered i.a. every four weeks, for a total of three administrations. |
| LRX712 | EXPERIMENTAL | LRX712 given intra-articularly |
| Name | Type | Description |
|---|---|---|
| LRX712 | DRUG | LRX712 intra-articular injections |
| Placebo | OTHER | Placebo intra-articular injections |
Inclusion Criteria: Written informed consent must be obtained before any assessment is performed. To be eligible for inclusion in this study patients must meet all of the following criteria: * Patient must have a BMI between 18 -35 kg/m2 * Patient must have symptomatic knee osteoarthritis predomi...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
LRX712 is an investigational small molecule being developed for osteoarthritis (OA), specifically studied in patients with moderate knee osteoarthritis aged 30 to 65 years. It is administered via intra-articular injection and is currently in clinical development for this musculoskeletal condition.
LRX712 is being developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker NVS. The drug is in clinical trials for knee osteoarthritis.
LRX712 is in Phase 2 clinical development for knee osteoarthritis. It has completed a Phase 1 first-in-human study and a Phase 2 study evaluating safety, tolerability, and preliminary efficacy of multiple intra-articular injections in patients with knee OA.
LRX712 has been studied in two completed clinical trials. NCT03355196 was a Phase 1 first-in-human study of safety, tolerability, and pharmacokinetics in osteoarthritic patients. NCT04097379 was a Phase 2 study of multiple intra-articular injections in patients with knee OA. Both trials were conducted in the Netherlands.
LRX712 is administered via intra-articular injection, meaning it is injected directly into the knee joint. This route of administration was used in both the Phase 1 and Phase 2 clinical trials for knee osteoarthritis.
LRX712 is not FDA approved. It is an investigational drug currently in clinical development for knee osteoarthritis. Its clinical trials have been completed, but the drug has not received regulatory approval for any indication.